Diasorin's shares have experienced a 0.60% decline after UBS downgraded the stock from "buy" to "neutral."
UBS analysts noted that Diasorin had made significant financial and operational improvements in the previous fiscal year, surpassing expectations. This positive performance has led to increased investor confidence in the company's management and strategic direction.
However, the stock is currently trading at a premium compared to the sector's historical average.